Access to SNDX-5613 to Treat People with Leukemia


Full Title

SNDX-5613-0707: Expanded Access Program for SNDX-5613 in Patients with Relapsed/Refractory Acute Leukemias with Genetic Alterations Associated with HOXA Overexpression (EAP)


Researchers in this study are making the drug SNDX-5613 available to more people with leukemia. The people in this study have a type of leukemia called mixed lineage leukemia (MLL)-rearranged acute lymphocytic leukemia (ALL). Their leukemia keeps growing even after treatment. Some people in the study have already been taking SNDX-5613 through a clinical trial and can continue taking it.

SNDX-5613 stops a protein called menin from attaching to other proteins called MLL1. Interactions between menin and MLL1 proteins make leukemia get worse. SNDX-5613 may slow cancer growth by blocking these interactions. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have MLL-rearranged ALL that keeps growing even with treatment, or have already been taking SNDX-5613 through a clinical trial.
  • Be age 1 month or more.


For more information or to see if you can join this study, please call Dr. Eytan Stein’s office at 646-608-3749.



Disease Status

Relapsed or Refractory


Co-Investigators ID